Adocia announces expanded BioChaperone® product portfolio beyond diabetes
- Following its successful application to diabetes treatments, BioChaperone® technology will now be deployed in a selected range of injectable therapeutics across numerous therapeutic areas
- Initial programs added to the portfolio include a ready-to-inject version of teduglutide for the treatment of short bowel syndrome and a fixed dose combination of glucagon and exenatide for the treatment of obesity
- Expansion of the portfolio creates new partnership opportunities
Adocia (Euronext Paris: FR0011184241- ADOC), the clinical biopharmaceutical company focused on developing innovative formulations of approved proteins for the treatment of diabetes and other metabolic diseases, today announced an update of its corporate strategy. The Company, which has built one of the most differentiated portfolio of injectable diabetes therapies, is expanding application of its proprietary BioChaperone® technology to new therapeutic areas.